Author of

• 20152

  +

  P1.03 - Chemotherapy/Targeted Therapy (ID 689)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Chemotherapy/Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 22588

    +

    P1.03-033 - Long-Term Outcome of Histoculture Drug Response Assay Guided Adjuvant Chemotherapy in Patients with Non-Small Cell Lung Cancer (ID 9259)

    09:30 - 09:30  |  Presenting Author(s): Yoshimitsu Hirai
    • Abstract

    Background:
    Histoculture Drug Response Assay (HDRA) is a representative in vitro drug response assay used for anticancer agents. Several papers reported that HDRA was useful to predict chemosensitivities in non-small cell lung cancer (NSCLC). However, it is unknown that whether HDRA truly predict clinical outcome and associate with other predictive markers, such as ERCC1 and class III beta-tubulin (TUBB3).
    
    Method:
    Between August 2007 to July 2009, 46 patients with non-small cell lung cancer who underwent surgical treatment were enrolled. HDRA technique was the same as we previously reported (JTCVS 133: 303-8, 2007). Chemosensitivities of cisplatin (CDDP), paclitaxel (PTX), docetaxel (DTX), and vinorelbine (VNR) were evaluated. Immunohistochemical staining for ERCC1 and TUBB3 were done using monoclonal antibody clone 8F1 and TUJ1. The H-score was adopted for the evaluation of ERCC1 and TUBB3 expression. Adjuvant therapy was selected for each patient based on HDRA within the standard treatment. Median follow up period was 117 months.
    
    Result:
    ERCC1 was positive in 38 specimens and negative 6 specimens. Inhibition rate for CDDP in HDRA was significantly lower (p=0.02) in ERCC1-positive specimens (41±16)% than in ERCC1-negative specimens (58±8%). TUBB3 was positive in 12 specimens and negative 32 specimens. Inhibition rate for VNR in HDRA was significantly higher (p=0.01) in TUBB3-positive specimens (38±17)% than in TUBB3-negative specimens (23±15%).However, inhibition rate for PTX and DTX were not significantly correlated with TUBB3 status (p=0.39, 0.94).Disease -free survival(DFS) in patients from IB to IIIA with HDRA guided therapy tended to be longer than those without HDRA (p=0.083). Overall survival (OS) in patients from IB to IIIA with HDRA guided therapy were not to be longer than those without HDRA (p=0.77).
    
    Conclusion:
    Tumors with low ERCC1 levels exhibited greater chemosensitivity to CDDP than tumors with high ERCC1 levels. Tumors with high TUBB3 levels exhibited greater chemosensitivity to VNR than tumors with low TUBB3 levels. HDRA-guided adjuvant chemotherapy may prolonged RFS, but not affect to OS.